Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT) and Replimune Group (REPL)

TipRanksSep 11 21:00

Replimune Group (REPL) Receives a Buy From Kempen & Co

TipRanksSep 11 18:05

Replimune to Present at the Cantor Global Healthcare Conference 2026

WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today

GlobeNewswireSep 3 20:00

Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight

The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer

PR NewswireAug 26 22:41

J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $21

J.P. Morgan analyst Anupam Rama maintains $Replimune(REPL.US)$ with a buy rating, and adjusts the target price from $20 to $21.According to TipRanks data, the analyst has a success rate of 55.0% and

Futu NewsAug 26 20:31

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02